AnaptysBio, Inc.

NasdaqGS:ANAB 주식 보고서

시가총액: US$677.5m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

AnaptysBio 미래 성장

Future 기준 확인 1/6

AnaptysBio 의 수익은 연간 14.9% 감소할 것으로 예상되는 반면, 연간 수익은 19.2% 로 증가할 것으로 예상됩니다. 19.2% 연간. EPS는 연간 1.6% 만큼 쇠퇴할 것으로 예상됩니다.

주요 정보

-14.9%

수익 성장률

-1.6%

EPS 성장률

Biotechs 수익 성장24.2%
매출 성장률19.2%
향후 자기자본 수익률n/a
애널리스트 커버리지

Good

마지막 업데이트21 Jun 2024

최근 미래 성장 업데이트

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

May 12
Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

Recent updates

News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

May 22
News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

May 12
Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Feb 22
Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Oct 10
Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%

May 24
AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%

Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?

Apr 27
Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Jan 10
Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial

Oct 05

Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

Sep 14
Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

AnaptysBio sells royalties from GSK-partnered Zejula for $45M

Sep 12

AnaptysBio (NASDAQ:ANAB) Is In A Good Position To Deliver On Growth Plans

Sep 01
AnaptysBio (NASDAQ:ANAB) Is In A Good Position To Deliver On Growth Plans

AnaptysBio skin condition candidate fails mid-stage trial; shares down 16%

Aug 31

AnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4M

Aug 08

Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates

May 10
Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Mar 16
Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

AnaptysBio's (NASDAQ:ANAB) Performance Is Even Better Than Its Earnings Suggest

Nov 11
AnaptysBio's (NASDAQ:ANAB) Performance Is Even Better Than Its Earnings Suggest

AnaptysBio (NASDAQ:ANAB) Is In A Strong Position To Grow Its Business

Jul 28
AnaptysBio (NASDAQ:ANAB) Is In A Strong Position To Grow Its Business

Upgrade: Analysts Just Made A Dazzling Increase To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

May 09
Upgrade: Analysts Just Made A Dazzling Increase To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

AnaptysBio EPS beats by $0.03, beats on revenue

May 04

Industry Analysts Just Made A Huge Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts

Mar 10
Industry Analysts Just Made A Huge Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts

AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Are Pretty Bullish On The Stock After Recent Results

Feb 28
AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Are Pretty Bullish On The Stock After Recent Results

Companies Like AnaptysBio (NASDAQ:ANAB) Are In A Position To Invest In Growth

Feb 10
Companies Like AnaptysBio (NASDAQ:ANAB) Are In A Position To Invest In Growth

Why AnaptysBio's (NASDAQ:ANAB) CEO Pay Matters

Dec 19
Why AnaptysBio's (NASDAQ:ANAB) CEO Pay Matters

수익 및 매출 성장 예측

NasdaqGS:ANAB - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/202631-240-270-2027
12/31/202524-208-146-17310
12/31/202441-163-90-9010
3/31/202423-163-134-133N/A
12/31/202317-164-122-121N/A
9/30/202315-148-98-97N/A
6/30/202313-144-79-78N/A
3/31/202311-137-78-77N/A
12/31/202210-129-74-74N/A
9/30/20224-135-88-88N/A
6/30/202224-108-78-77N/A
3/31/202253-76-45-44N/A
12/31/202163-58-47-46N/A
9/30/202112281517N/A
6/30/2021101-957N/A
3/31/202171-30-23-22N/A
12/31/202075-20-15-14N/A
9/30/202018-74-68-68N/A
6/30/202018-81-73-73N/A
3/31/202023-84-69-69N/A
12/31/20198-97-70-70N/A
9/30/20195-94-67-66N/A
6/30/201910-79-60-59N/A
3/31/20195-69-53-52N/A
12/31/20185-62-50-49N/A
9/30/20188-52-42-41N/A
6/30/20183-45-31-30N/A
3/31/201810-34-24-24N/A
12/31/201710-30N/A-19N/A
9/30/201710-27N/A-20N/A
6/30/201713-19N/A-19N/A
3/31/201712-15N/A-15N/A
12/31/201617-4N/A-9N/A
9/30/201618-4N/A-6N/A
6/30/201619-4N/A-5N/A
3/31/201618-6N/A-9N/A
12/31/201518-5N/A-10N/A
9/30/201517-2N/A-6N/A
6/30/2015190N/A-4N/A
3/31/2015181N/A-3N/A
12/31/2014160N/A15N/A
12/31/20135-6N/A-6N/A

애널리스트 미래 성장 예측

수입 대 저축률: ANAB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: ANAB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: ANAB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: ANAB 의 수익(연간 19.2% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: ANAB 의 수익(연간 19.2% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: ANAB 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.


성장 기업 발견